Research Analysts Offer Predictions for DAWN Q1 Earnings

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) – Stock analysts at HC Wainwright lifted their Q1 2025 EPS estimates for shares of Day One Biopharmaceuticals in a research note issued to investors on Wednesday, February 26th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of ($0.28) per share for the quarter, up from their previous forecast of ($0.34). HC Wainwright has a “Buy” rating and a $36.00 price objective on the stock. The consensus estimate for Day One Biopharmaceuticals’ current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Day One Biopharmaceuticals’ Q2 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.94) EPS, FY2026 earnings at $0.34 EPS, FY2027 earnings at $0.58 EPS, FY2028 earnings at $1.21 EPS and FY2029 earnings at $1.73 EPS.

Several other research analysts have also recently weighed in on the stock. TD Cowen raised shares of Day One Biopharmaceuticals to a “strong-buy” rating in a research report on Monday, November 4th. Bank of America lowered their price target on shares of Day One Biopharmaceuticals from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, January 7th. Needham & Company LLC reissued a “buy” rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday. The Goldman Sachs Group lowered their price target on shares of Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating on the stock in a research report on Monday, February 10th. Finally, Wedbush reissued an “outperform” rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Day One Biopharmaceuticals currently has a consensus rating of “Buy” and an average target price of $34.86.

Day One Biopharmaceuticals Stock Down 4.0 %

Shares of DAWN opened at $9.06 on Friday. Day One Biopharmaceuticals has a 52-week low of $9.02 and a 52-week high of $18.07. The firm’s fifty day moving average is $12.16 and its two-hundred day moving average is $13.38. The stock has a market cap of $913.66 million, a PE ratio of -8.80 and a beta of -1.46.

Day One Biopharmaceuticals (NASDAQ:DAWN) last announced its earnings results on Tuesday, February 25th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.34). The business had revenue of $29.21 million for the quarter, compared to the consensus estimate of $27.11 million.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, General Counsel Adam Dubow sold 4,646 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $11.96, for a total value of $55,566.16. Following the transaction, the general counsel now owns 39,602 shares of the company’s stock, valued at $473,639.92. This represents a 10.50 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Samuel C. Blackman sold 30,000 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $13.31, for a total transaction of $399,300.00. Following the completion of the transaction, the insider now directly owns 1,034,015 shares in the company, valued at $13,762,739.65. The trade was a 2.82 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 51,064 shares of company stock valued at $651,225 over the last 90 days. 8.40% of the stock is owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of DAWN. GF Fund Management CO. LTD. acquired a new position in Day One Biopharmaceuticals in the fourth quarter valued at about $27,000. R Squared Ltd purchased a new stake in Day One Biopharmaceuticals during the fourth quarter worth about $31,000. Mirae Asset Global Investments Co. Ltd. increased its stake in Day One Biopharmaceuticals by 38.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,611 shares of the company’s stock worth $51,000 after purchasing an additional 1,002 shares during the period. Quest Partners LLC increased its stake in Day One Biopharmaceuticals by 9,238.6% during the third quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock worth $108,000 after purchasing an additional 7,668 shares during the period. Finally, Tower Research Capital LLC TRC increased its stake in Day One Biopharmaceuticals by 911.1% during the fourth quarter. Tower Research Capital LLC TRC now owns 10,657 shares of the company’s stock worth $135,000 after purchasing an additional 9,603 shares during the period. Institutional investors and hedge funds own 87.95% of the company’s stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.